Eli Lilly is trading at ARS 37,580.00, up 4.27%, amid a broader healthcare rally.
- Healthcare stocks are up 2.12% during the regular session as investors rotate away from technology stocks.
- The European Medicines Agency committee recommended Eli Lillyβs oral Foundayo for EU approval, which may support sentiment.
- Available reporting does not establish the recommendation as the cause of the October 20 move; the European Commission still makes the final decision.